Bank of Stockton Raises Stake in AstraZeneca PLC (NASDAQ:AZN)

Bank of Stockton lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 48.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 4,142 shares of the company’s stock after buying an additional 1,356 shares during the period. Bank of Stockton’s holdings in AstraZeneca were worth $323,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brookstone Capital Management acquired a new position in AstraZeneca in the first quarter valued at $315,000. Wealthcare Advisory Partners LLC increased its stake in shares of AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock valued at $416,000 after acquiring an additional 543 shares during the last quarter. Janiczek Wealth Management LLC lifted its holdings in shares of AstraZeneca by 23.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 980 shares of the company’s stock worth $66,000 after acquiring an additional 184 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of AstraZeneca by 57.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 181,601 shares of the company’s stock worth $12,303,000 after acquiring an additional 66,181 shares during the period. Finally, Thrive Wealth Management LLC grew its holdings in AstraZeneca by 5.0% in the first quarter. Thrive Wealth Management LLC now owns 4,020 shares of the company’s stock valued at $272,000 after purchasing an additional 192 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Down 0.4 %

Shares of NASDAQ AZN traded down $0.33 on Friday, hitting $75.57. The company had a trading volume of 1,041,323 shares, compared to its average volume of 4,998,334. The firm has a market capitalization of $234.31 billion, a P/E ratio of 36.67, a PEG ratio of 1.43 and a beta of 0.46. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The business has a 50 day moving average of $80.59 and a two-hundred day moving average of $78.39.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. AstraZeneca’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $1.08 earnings per share. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. TD Cowen upped their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.